Author Archives: Jose Marques Lopes PhD

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 and older, with at least one F508del mutation in two Phase 3 studies, according to Vertex Pharmaceuticals. This…

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Suggests

Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitro efficacy against multidrug-resistant Pseudomonas aeruginosa collected from the sputum of cystic fibrosis (CF) patients, according to a recent study. The study, “Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam,” was…


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.